In models of renal, hepatic, and pulmonary fibrosis, the use of 4-methylumbelliferone (4-MU)—an inhibitor of HA synthesis—led to a reduction in its deposition in the tissue and indirect quenching of CD44 signaling. This evidence concerns the gene CD44 and pulmonary fibrosis.